Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

被引：0
|
作者：
Norbert Vey
Hagop Kantarjian
Miloslav Beran
Susan O'Brien
Jorge Cortes
Charles Koller
Elihu Estey
机构：
[1] University of Texas,Leukemia Department, Division of Medicine
[2] M.D. Anderson Cancer Center,undefined
来源：
Investigational New Drugs | 1999年 / 17卷
关键词：
acute myeloid leukemia; salvage therapy; topotecan; etoposide; cytosine arabinoside;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The topoisomerase I inhibitor topotecan has shown activity in acute myeloid leukemia (AML) and myelodysplastic syndromes. The present study was designed to assess whether topotecan with cytosine arabinoside (ara-C) or with etoposide (VP-16) should be studied in phase II trials in patients with refractory or relapsed AML.
引用
收藏
页码：89 / 95
页数：6
相关论文
共 50 条
  • [1] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Koller, C
    Estey, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 89 - 95
  • [2] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [3] Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia
    Chen, Xiaomei
    Weng, Jianyu
    Wang, Yulian
    Deng, Chengxin
    Luo, Chengwei
    Liao, Pengjun
    Li, Minming
    Huang, Xin
    Lai, Peilong
    Huang, Lisi
    Cao, Zhi
    Wan, Changchun
    Zhong, Liye
    Wu, Suijing
    Lu, Zesheng
    Zou, Xiaoli
    Du, Xin
    BLOOD, 2015, 126 (23)
  • [4] APhase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
    Advani, Anjali S.
    Cooper, Brenda
    Visconte, Valeria
    Elson, Paul
    Chan, Ricky
    Carew, Jennifer
    Wei, Wei
    Mukherjee, Sudipto
    Gerds, Aaron
    Carraway, Hetty
    Nazha, Aziz
    Hamilton, Betty
    Sobecks, Ronald
    Caimi, Paolo
    Tomlinson, Benjamin
    Malek, Ehsan
    Little, Jane
    Miron, Alexander
    Pink, John
    Maciejewski, Jaroslaw
    Unger, Allison
    Kalaycio, Matt
    de Lima, Marcos
    Sekeres, Mikkael A.
    CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4231 - 4237
  • [5] A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Griffiths, Elizabeth A.
    Brady, William
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Sperrazza, Jill
    Wang, Eunice S.
    Wetzler, Meir
    BLOOD, 2014, 124 (21)
  • [6] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [7] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
    Klisovic, Rebecca B.
    Wang, Hongyan
    Walker, Alison
    Walsh, Katherine
    Vasu, Sumithira
    Garzon, Ramiro
    Devine, Steven M.
    Wang, Jiang
    Garr, Celia
    Norris, Adam
    Byrd, John C.
    Grever, Michael R.
    Blum, William
    Chan, Kenneth K.
    Marcucci, Guido
    BLOOD, 2012, 120 (21)
  • [8] A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Kuchroo, Manik Razdan
    Redd, Robert A.
    Garcia, Jacqueline S.
    Keng, Michael
    Hobbs, Gabriela S.
    Rosenblatt, Jacalyn
    Luskin, Marlise R.
    Narayan, Rupa
    Amrein, Philip C.
    McMasters, Malgorzata
    Wadleigh, Martha
    Hock, Hanno
    Stone, Richard
    Neuberg, Donna S.
    Avigan, David
    Ballen, Karen K.
    Fathi, Amir T.
    DeAngelo, Daniel J.
    Brunner, Andrew M.
    BLOOD, 2023, 142
  • [9] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
    Advani, Anjali
    Elson, Paul
    Hsi, Eric D.
    Davis, Randall
    Kalaycio, Matt
    Sobecks, Ronald
    Copelan, Edward
    Duong, Hien K.
    Foster, Bethany
    Rush, Mary Lynn
    Farhat, Leslie
    Sekeres, Mikkael A.
    BLOOD, 2012, 120 (21)
  • [10] A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia
    Cooper, BW
    Donaher, E
    Lazarus, HM
    Green, SB
    Gosky, DM
    Rosenthal, NS
    Berger, SJ
    Li, XL
    Ingalls, ST
    Hoppel, CL
    Gerson, SL
    LEUKEMIA RESEARCH, 2003, 27 (01) : 35 - 44
12345